Transmucosal penetration of bismuth particles in the human stomach
- PMID: 1727749
- DOI: 10.1016/0016-5085(92)91796-7
Transmucosal penetration of bismuth particles in the human stomach
Abstract
Electron microscopic examination of upper gastrointestinal biopsies with x-ray microanalysis was used to detect electron-dense particles of bismuth in the mucosa of the upper gastrointestinal tract, 30-60 minutes after oral dosing with either tripotassium dicitrato bismuthate [De-Noltab; Brocades (Great Britain) Ltd., Weybridge, UK; five patients] or bismuth salicylate (Pepto-Bismol; Richardson Vicks Ltd., Egham, UK; five patients), or without dosing (two patients). Transmucosal penetration of bismuth particles was observed in the gastric antral mucosa of all patients who had been dosed with tripotassium dicitrato bismuthate, but there was no penetration after oral dosing with bismuth salicylate. Persorption of bismuth particles through the gastric mucosa to the vascular endothelium provides an explanation for the rapid rise of plasma bismuth concentration observed only after oral dosing with tripotassium dicitrato bismuthate.
Comment in
-
Bismuth absorption from the stomach and small intestine.Gastroenterology. 1992 Jun;102(6):2192-3. doi: 10.1016/0016-5085(92)90380-h. Gastroenterology. 1992. PMID: 1587454 No abstract available.
-
The mechanism of bismuth absorption.Gastroenterology. 1993 Apr;104(4):1242-3. doi: 10.1016/0016-5085(93)90324-6. Gastroenterology. 1993. PMID: 8462822 No abstract available.
Similar articles
-
The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds.Gastroenterology. 1991 Oct;101(4):889-94. doi: 10.1016/0016-5085(91)90712-t. Gastroenterology. 1991. PMID: 1889712 Clinical Trial.
-
Gastric persorption of bismuth from ranitidine bismuth citrate.Aliment Pharmacol Ther. 1995 Aug;9(4):447-50. doi: 10.1111/j.1365-2036.1995.tb00404.x. Aliment Pharmacol Ther. 1995. PMID: 8527622 Clinical Trial.
-
Comparison of one-day oral dosing with three bismuth compounds for the suppression of Helicobacter pylori assessed by the 13C-urea breath test.Aliment Pharmacol Ther. 1992 Feb;6(1):97-102. doi: 10.1111/j.1365-2036.1992.tb00549.x. Aliment Pharmacol Ther. 1992. PMID: 1543820
-
Bismuth subsalicylate: history, chemistry, and safety.Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S3-8. doi: 10.1093/clinids/12.supplement_1.s3. Rev Infect Dis. 1990. PMID: 2406853 Review.
-
Review article: safety of bismuth in the treatment of gastrointestinal diseases.Aliment Pharmacol Ther. 1996 Aug;10(4):459-67. doi: 10.1046/j.1365-2036.1996.22163000.x. Aliment Pharmacol Ther. 1996. PMID: 8853750 Review.
Cited by
-
Engineered nanomaterials: exposures, hazards, and risk prevention.J Occup Med Toxicol. 2011 Mar 21;6:7. doi: 10.1186/1745-6673-6-7. J Occup Med Toxicol. 2011. PMID: 21418643 Free PMC article.
-
Indications for treatment of Helicobacter pylori infection: a systematic overview.CMAJ. 1994 Jan 15;150(2):189-98. CMAJ. 1994. PMID: 8287341 Free PMC article. Review.
-
Pharmacokinetic considerations in the eradication of Helicobacter pylori.Clin Pharmacokinet. 2000 Mar;38(3):243-70. doi: 10.2165/00003088-200038030-00004. Clin Pharmacokinet. 2000. PMID: 10749519 Review.
-
Drug-drug interaction profiles of proton pump inhibitors.Clin Pharmacokinet. 2010 Aug;49(8):509-33. doi: 10.2165/11531320-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608754 Review.
-
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.Drug Saf. 1996 Jul;15(1):30-52. doi: 10.2165/00002018-199615010-00003. Drug Saf. 1996. PMID: 8862962 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources